Dialysis patients may benefit from ergothioneine supplement

NCT ID NCT06487546

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily ergothioneine supplement can replenish low levels of this nutrient in people with kidney failure who are on dialysis. Dialysis removes waste but also strips away beneficial chemicals like ergothioneine. Researchers will give 28 participants either the supplement or a placebo for 12 weeks and measure blood levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ergothioneine (dietary supplement)
What this could lead to: If it works, this could show that a simple supplement helps restore a nutrient that dialysis removes, potentially improving health in kidney failure patients.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply widely. The supplement may not raise levels enough or have any clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESRD

Contacts and locations

Locations

Veterans Affairs Palo Alto
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.